← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA319.8x17.0x22.3x
EV / LTM revenue601.1x2.3x5.3x
Premium to unaffected price6629%35%53%
Premium to 30-day VWAP1229%51%66%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
08162009: 1 deals, 0 clean on every measure200912010: 16 deals, 2 clean on every measure2010162011: 14 deals, 4 clean on every measure2011142012: 8 deals, 6 clean on every measure201282013: 10 deals, 7 clean on every measure2013102014: 7 deals, 2 clean on every measure201472015: 11 deals, 9 clean on every measure2015112016: 3 deals, 3 clean on every measure201632017: 9 deals, 8 clean on every measure201792018: 8 deals, 4 clean on every measure201882019: 4 deals, 0 clean on every measure201942020: 5 deals, 2 clean on every measure202052021: 8 deals, 2 clean on every measure202182022: 14 deals, 9 clean on every measure2022142023: 7 deals, 3 clean on every measure202372024: 12 deals, 6 clean on every measure2024122025: 15 deals, 10 clean on every measure2025152026: 8 deals, 6 clean on every measure20268
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 17.0x median across 31 dealsHealthcare17.0xn=31Utilities: 16.1x median across 15 dealsUtilities16.1xn=15Technology: 15.3x median across 66 dealsTechnology15.3xn=66Real Estate: 13.8x median across 27 dealsReal Estate13.8xn=27Business Services: 13.4x median across 42 dealsBusiness Services13.4xn=42Industrials: 12.7x median across 38 dealsIndustrials12.7xn=38Financials: 11.9x median across 10 dealsFinancials11.9xn=10Consumer & Retail: 11.2x median across 58 dealsConsumer & Retail11.2xn=58Materials: 9.5x median across 15 dealsMaterials9.5xn=15Energy: 8.4x median across 11 dealsEnergy8.4xn=11Media & Telecom: 6.9x median across 18 dealsMedia & Telecom6.9xn=18Other: 5.8x median across 11 dealsOther5.8xn=11
Deals by sector
Technology: 198 dealsTechnology198Financials: 160 dealsFinancials160Healthcare: 160 dealsHealthcare160Consumer & Retail: 125 dealsConsumer & Retail125Real Estate: 107 dealsReal Estate107Industrials: 103 dealsIndustrials103Business Services: 96 dealsBusiness Services96Energy: 60 dealsEnergy60Media & Telecom: 55 dealsMedia & Telecom55Materials: 45 dealsMaterials45Other: 42 dealsOther42Utilities: 42 dealsUtilities42
Deals by buyer type
Financial sponsor: 18 dealsFinancial sponsor18Strategic: 256 dealsStrategic256Management / founder: 1 dealsManagement / founder1Controlling holder: 2 dealsControlling holder2Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 160 dealsUnclassified160
Deals by enterprise value
Under $250m: 74 dealsUnder $250m74$250m to $1bn: 29 deals$250m to $1bn29$1bn to $5bn: 34 deals$1bn to $5bn34$5bn to $20bn: 18 deals$5bn to $20bn18Over $20bn: 5 dealsOver $20bn5Not computed: 0 dealsNot computed0
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 95 dealsChemicals, Pharmaceutic…95Health Services: 35 dealsHealth Services35Instruments, Medical Devices & Optical Goods: 30 dealsInstruments, Medical De…30
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Sierra Oncology, Inc.
2022-04-12 · Public merger · $55.00 a share
Not named in the filing
Unclassified
Healthcare$1.0bnn.a.n.a.
39%
63% to VWAP
DEFM14A
All cash
Ortho Clinical Diagnostics Holdings plc
2022-04-11 (filed) · Public merger · $7.14 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$3.7bn7.5xn.a.
n.a.
DEFM14A
Includes stock
Quidel Corp /de/
2022-04-11 (filed) · Public merger · $7.14 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM EBITDA -0.8x outside 1x to 75x
Not named in the filing
Unclassified
Healthcare-$1.0bn-0.8x-0.4x
n.a.
DEFM14A
Includes stock
Tivity Health, Inc.
2022-04-05 · Public merger · $32.50 a share
Titan-Atlas Parent, Inc.
Unclassified
Healthcare$1.9bn12.5x3.8x
n.a.
DEFM14A
All cash
SOC Telemed, Inc.
2022-02-02 · Public merger · $3.00 a share
Spark Parent, Inc.
Unclassified
Healthcare$264mn.a.2.8x
n.a.
DEFM14A
All cash
GeneDx Holdings Corp.
2022-01-14 · Public merger · $4.04 a share
Merger Subs
Unclassified
Healthcare$585mn.a.2.8x
n.a.
DEFM14A
All cash
Trillium Therapeutics Inc.
2021-09-27 (filed) · Public merger · $18.50 a share
Held out of the premiums: premium of 204%: distressed or misread
Not named in the filing
Unclassified
Healthcare$1.7bnn.a.n.a.
204%
DEFM14A
All cash
Xeris Pharmaceuticals Inc
2021-07-29 (filed) · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$38mn.a.1.1x
n.a.
DEFM14A
Includes stock
Strongbridge Biopharma plc
2021-07-29 (filed) · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$22mn.a.0.6x
n.a.
DEFM14A
Includes stock
Ayala Pharmaceuticals, Inc.
2021-07-04 · Public merger · $26.91 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 1290.3x above 60x
Not named in the filing
Unclassified
Healthcare$3.9bnn.a.1290.3x
n.a.
DEFM14A
Includes stock
Intec Pharma Ltd.
2021-04-27 · Public merger · $7.02 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$22mn.a.n.a.
n.a.
DEFM14A
Includes stock
CRH Medical Corp
2021-03-19 (filed) · Public merger · $4.00 a share
Not named in the filing
Unclassified
Healthcare$354m10.4x3.3x
83%
DEFM14A
All cash
Gw Pharmaceuticals plc
2021-03-15 (filed) · Public merger · $16.66 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$5.8bnn.a.11.0x
53%
DEFM14A
Includes stock
Oxford Immunotec Global PLC
2021-01-29 (filed) · Public merger · $22.00 a share
Not named in the filing
Unclassified
Healthcare$411mn.a.7.2x
n.a.
DEFM14A
All cash
Tottenham Acquisition I Ltd
2020-12-18 (filed) · Public merger · $10.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; no balance sheet at announcement: EV = equity value
Not named in the filing
Unclassified
Healthcare$37mn.a.n.a.
n.a.
DEFM14A
Includes stock
Alexion Pharmaceuticals, Inc.
2020-12-12 · Public merger · $60.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$13bn15.0x2.3x
n.a.
DEFM14A
Includes stock
American Renal Associates Holdings, Inc.
2020-10-01 · Public merger · $11.50 a share
IRC Superman Midco, LLC, LLC
Unclassified
Healthcare$842mn.a.1.0x
66%
DEFM14A
All cash
Wright Medical Group N.V.
2020-03-20 (filed) · Public merger · $30.75 a share
Not named in the filing
Unclassified
Healthcare$5.0bn65.5x5.4x
n.a.
50% to VWAP
DEFM14A
All cash
Progenics Pharmaceuticals Inc
2020-02-20 · Public merger · $5.03 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$432mn.a.12.3x
n.a.
52% to VWAP
DEFM14A
Includes stock
Larimar Therapeutics, Inc.
2019-12-17 · Public merger · $5000.00 a share
Held out of every statistic: consideration of $5,000.00 per share: not a per-share figure; consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$187bnn.a.n.a.
n.a.
DEFM14A
Includes stock
Ra Pharmaceuticals, Inc.
2019-10-09 · Public merger · $48.00 a share
Held out of the multiples: EV / LTM revenue 785.6x above 60x
Not named in the filing
Unclassified
Healthcare$2.0bnn.a.785.6x
111%
DEFM14A
All cash
Allergan plc
2019-09-16 (filed) · Public merger · $120.30 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$60bnn.a.3.8x
n.a.
DEFM14A
Includes stock
Versum Materials, Inc.
2019-01-27 · Public merger · $48.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$5.8bn13.4x4.2x
11%
DEFM14A
Includes stock
Avenue Therapeutics, Inc.
2018-12-21 (filed) · Public merger · $13.92 a share
Held out of the premiums: premium of 235%: distressed or misread
Not named in the filing
Unclassified
Healthcare$144mn.a.n.a.
235%
DEFM14A
All cash
Adynxx, Inc.
2018-10-11 · Public merger · $5.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$14mn.a.1.9x
n.a.
DEFM14A
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More